Applied BioCode Capital Reinvestment Ratio

Latest as of September 2022: 1.89x

Applied BioCode capital reinvestment ratio. Applied BioCode (6598) has a Capital Reinvestment Ratio of 1.89x as of September 2022, meaning it reinvests 2% of its operating cash flow (NT$6.35 Million) in capital expenditures (NT$12.00 Million). Check Applied BioCode cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

1.89x
Capex / Operating Cash Flow

Operating Cash Flow

NT$6.35 Million
TWD

Capital Expenditures

NT$12.00 Million
TWD

Data as of

Sep 2022
Most recent filing

Capital Reinvestment Ratio of Applied BioCode (2022–2022)

Capital reinvestment ratio of Applied BioCode from 2022 to 2022. This chart tracks Applied BioCode's Capital Reinvestment Ratio across 1 annual periods. Also explore 6598 net asset momentum to track the company's year-over-year net asset growth rate.

Applied BioCode Capital Reinvestment Ratio by Year (2022–2022)

Applied BioCode capital reinvestment ratio by year from 2022 to 2022. For the full cash flow conversion analysis, see cash flow conversion of Applied BioCode.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2022 0.15x NT$145.87 Million NT$22.14 Million —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow